

## Special Issue

# The Pleiotropic Effects of Statins: Anti-Inflammatory, Anti-Coagulant, and Anti-Proliferative Properties

### Message from the Guest Editor

In addition to their cholesterol-lowering capabilities, statins exhibit pleiotropic effects that are beneficial in various non-cardiovascular diseases. Their anti-inflammatory properties are particularly useful in conditions like rheumatoid arthritis and systemic lupus erythematosus, where they reduce the levels of pro-inflammatory cytokines such as TNF- $\alpha$  and IL-6. Statins also demonstrate anti-coagulant effects by decreasing tissue factor expression, which can be beneficial in preventing thromboembolic events in diseases like deep vein thrombosis. Additionally, their anti-proliferative properties are being explored in cancer treatment, as they inhibit the proliferation of certain cancer cells by targeting pathways like Rho/ROCK and PPARs. These diverse effects make statins a versatile therapeutic option in managing a range of diseases beyond their traditional use in cardiovascular health.

### Guest Editor

Dr. Maria Grau

1. Department of Medicine, School of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain
2. Biomedical Research Consortium in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain

### Deadline for manuscript submissions

31 January 2026



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/244771](https://mdpi.com/si/244771)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).